Bristol-Myers Squibb Company / Philochem AG

Metastatic Castration-Resistant Prostate Cancer (mCRPC) - radioligand therapy

314K US cases/yr · $1.4B Pluvicto 2024 global revenue (Novartis 10-K), proxy for mCRPC radioligand market · ~15-25% Share of mCRPC patients who are PSMA-low/heterogeneous (addressable by alternative ligands like ACP3)

Disease Overview

Prostate cancer is the most commonly diagnosed solid tumor in American men, with the American Cancer Society projecting approximately 313,780 new US cases and 35,770 deaths in 2025. Metastatic castration-resistant prostate cancer (mCRPC) represents the lethal end-stage, reached by approximately 30,000-40,000 US men annually following progression on androgen deprivation therapy and novel hormonal agents (abiraterone, enzalutamide). Median overall survival in mCRPC is 2-3 years despite sequential taxane chemotherapy, PARP inhibitors for HRR-mutated disease, and radium-223. The 2022 approval of Novartis' Pluvicto (Lu-177 PSMA-617 radioligand therapy) in PSMA-positive mCRPC post-taxane validated targeted radiopharmaceuticals and generated $1.39B in 2024 revenue, with FDA label expansion into pre-taxane mCRPC (March 2025) driving further growth. However, approximately 15-25% of mCRPC patients are PSMA-low or PSMA-heterogeneous by PET imaging, limiting Pluvicto eligibility and creating a defined unmet need for alternative tumor-targeting ligands. Acid phosphatase 3 (ACP3, prostatic acid phosphatase) is a highly prostate-restricted enzyme with robust surface expression across PSMA-low and PSMA-high tumors, offering a complementary or alternative targeting strategy for next-generation radioligand therapy.

Competitive Landscape

The mCRPC radioligand therapy (RLT) landscape is dominated by Novartis' Pluvicto (Lu-177-PSMA-617), the first FDA-approved PSMA-targeted RLT (March 2022) with $1.39B 2024 revenue. Novartis' pipeline also includes Lu-177-PSMA-R2 and alpha-emitter Ac-225-PSMA-617 (ongoing trials). Direct PSMA-targeted competitors include Lantheus/POINT Biopharma's PNT2002 (Lu-177-PSMA-I&T, FDA NDA filed 2025), Telix Pharmaceuticals' TLX591 (Lu-177-rosopatamab, Phase 3 ProstACT Global), Fusion Pharmaceuticals/AstraZeneca's FPI-2059 (Ac-225-NTSR1, post-Fusion acquisition), Aktis Oncology's Ac-225 alpha programs, and RayzeBio's own RYZ101 (Ac-225-DOTATATE, in GEP-NETs and other indications). OncoACP3, a small-molecule ACP3-targeted ligand from Philochem (Philogen's radioligand subsidiary), is differentiated by targeting acid phosphatase 3, a prostate-restricted enzyme distinct from PSMA, potentially capturing PSMA-low patients and enabling theranostic imaging (F-18/Ga-68 PET) paired with Lu-177 or Ac-225 therapy. BMS gained RayzeBio via its $4.1B Dec-2023 acquisition and is deploying it as its radiopharma growth engine.